Evidence map›Paper›PMID 35932173›Full record

ArticleClinical cardiology2022

Adiponectin serum level is an independent and incremental predictor of all-cause mortality after transcatheter aortic valve replacement.

Jeroen Walpot, Paul van Herck, Valerie Collas, Liene Bossaerts, Caroline M Van de Heyning, Tom Vandendriessche, Hein Heidbuchel, Inez Rodrigus, Christophe De Block, Gary R Small and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jeroen WalpotDepartment of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.ORCID http://orcid.org/0000-0001-9226-545X
Paul van HerckDepartment of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.
Valerie CollasFaculty of Health Sciences and Medicine, University of Antwerp, Wilrijk, Belgium.
Liene BossaertsFaculty of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
Caroline M Van de HeyningDepartment of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-4661-4732
Tom VandendriesscheDepartment of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.
Hein HeidbuchelDepartment of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.
Inez RodrigusDepartment of Cardiac Surgery, University Hospital Antwerp, Antwerp, Edegem, Belgium.
Christophe De BlockDepartment of Endocrinology-Diabetology and Metabolism, Antwerp University Hospital, Edegem, Antwerp, Belgium.
Gary R SmallDivision of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Johan BosmansDepartment of Cardiology, University Hospital Antwerp, Edegem, Antwerp, Belgium.
Antwerp University Hospital · BEUniversity of Antwerp · BEUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundQuantifiable biomarkers may be useful for a better risk and frailty assessment of patients referred for transcatheter aortic valve implantation (TAVI). HYPOTHESIS: To determine if adiponectin serum concentration predicts all-cause mortality in patients undergoing TAVI.

methods77 consecutive patients, undergoing TAVI, were analyzed. The CT axial slices at the level of the fourth lumbar vertebra were used to measure the psoas muscle area, and its low-density muscle fraction (LDM (%)). To assess the operative risk, the STS (Society of Thoracic Surgeons Predicted Risk of Mortality) score, Log. Euroscore, and Euroscore II were determined. A clinical frailty assessment was performed. ELISA kits were used to measure adiponectin serum levels. We searched for a correlation between serum adiponectin concentration and all-cause mortality after TAVI.

resultsThe mean age was 80.8 ± 7.4 years. All-cause mortality occurred in 22 patients. The mean follow-up was 1779 days (range: 1572-1825 days). Compared with patients with the lowest adiponectin level, patients in the third tertile had a hazards ratio of all-cause mortality after TAVI of 4.155 (95% CI: 1.364-12.655) (p = .004). In the multivariable model, including STS score, vascular access of TAVI procedure, LDM (%), and adiponectin serum concentration, serum adiponectin level, and LDM(%) were independent predictors of all-cause mortality after TAVI (p = .178, .303, .042, and .017, respectively). Adiponectin level was a predictor of all-cause mortality in females and males (p = .012 and 0.024, respectively).

conclusionAdiponectin serum level is an independent and incremental predictor of all-cause mortality in patients undergoing TAVI.

Indexed as

Aortic Valve StenosisFrailtyTranscatheter Aortic Valve ReplacementAdiponectinAgedAged, 80 and overAortic ValveBiomarkersFemaleHumansMaleRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeAdiponectinBiomarkersadiponectinall-cause mortalitycytokinesfrailtypsoas muscle low-density muscle fractionSTS scoretranscatheter aortic valve replacement

Identifiers

PMID35932173
PMCPMC9574742
OpenAlexW4289979543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.